Novo Nordisk (NVO) cut its U.S. sales team focused on obesity and diabetes education for healthcare providers, Maggie Fick of Reuters reports, citing two sources close to the company and LinkedIn posts. The news is a sign of the company’s efforts to cut costs and regain market share on Eli Lilly (LLY), according to Reuters.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Morning Movers: Intel jumps following $5B investment from Nvidia
- Novo Nordisk Stock (NVO) Surges as Wegovy Pill Delivers Big Weight-Loss Gains
- Novo Nordisk publishes results from OASIS 4 trial of Wegovy in NEJM
- Eli Lilly (LLY) to File for Weight-Loss Pill Approval in Multiple Markets
- Novo Nordisk upgraded to Buy from Hold at Berenberg